Vivani Medical Earnings Call Transcripts
Fiscal Year 2025
-
A novel GLP-1 implant aims to address poor adherence and tolerability in obesity and diabetes care by offering infrequent, removable dosing and sustained drug release. Preclinical and early clinical data show promising safety and efficacy, with clinical trials set to begin next year.
-
A novel subdermal implant platform aims to address poor adherence and tolerability in GLP-1-based obesity and diabetes treatments, with clinical trials for a semaglutide implant set to begin next year. Preclinical and first-in-human data support safety, efficacy, and market interest.
-
The company presented updates on its proprietary implant technology for GLP-1 drug delivery, highlighting rapid clinical trial enrollment, strong preclinical results, and a robust patent portfolio. Key milestones are expected this year, with a focus on obesity and diabetes markets.
-
A six-month GLP-1 implant for weight management and diabetes is in first-in-human trials, with mid-year results expected. The NanoPortal platform, enabling controlled drug release, is being tested in humans for the first time and is licensable for broader use.
Fiscal Year 2024
-
NanoPortal technology enables precise, long-acting GLP-1 delivery, aiming to improve adherence and outcomes in obesity and diabetes. A Phase I study of the exenatide implant is set to begin in Q4, with interim data expected in early to mid-2025. Cash reserves support operations into the second half of next year.
-
A novel subdermal implant platform aims to improve chronic disease treatment adherence, starting with GLP-1 therapies for obesity and diabetes. Preclinical data show steady, long-term drug release and efficacy comparable to leading injectables, with first human trials set for late 2024.